PMID: 11604260Oct 18, 2001Paper

Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis

International Journal of Pharmaceutics
T P JohnstonS Shefer

Abstract

Poloxamer-407 (P-407) is a nonionic surfactant that induces atheroma formation in the aortas of C57BL/6 mice with long-term (14 weeks) administration. The objectives of the present study were to determine the mechanism(s) responsible for the induction of hypercholesterolemia as well as to determine whether this animal model may be of potential use in rank ordering the efficacy (lipid lowering) of various statin drugs. The effect of long-term (16 weeks) administration of P-407 on the catalytic activities of rate-limiting enzymes of cholesterol biosynthesis [HMG-CoA reductase (HMGR)] and catabolism [microsomal cholesterol 7alpha-hydroxylase (C7alphaH) and mitochondrial sterol 27 hydroxylase (S27H)] was assessed in C57BL/6 mice. Effects of P-407 on these enzymes were compared in mice fed an atheroma-inducing diet (high-cholesterol, supplemented with cholic acid) and animals maintained on a basal diet and injected with saline (controls) after 16 weeks. The mean value for the activities of C7alphaH in P-407-injected mice was 24.3+/-3.8 pmol min(-1) mg(-1) and was significantly (P<0.05) less than the mean value determined for sham-injected control animals (37.0+/-14.3 pmol min(-1) mg(-1)). In contrast, the mean values for the catalyt...Continue Reading

References

Apr 1, 1991·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G YoshinoS Baba
Mar 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·B PaigenD Albee
Jun 14, 1990·Biochimica Et Biophysica Acta·B V KhanM Heimberg
Mar 15, 1989·The Biochemical Journal·B KhanM Heimberg
Aug 1, 1988·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D W Quig, D B Zilversmit
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P T MaM S Brown
Feb 1, 1985·Experimental and Molecular Pathology·M P JokinenR W Prichard
Oct 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S SheferA K Batta
Aug 1, 1994·Current Opinion in Lipidology·B PaigenE M Rubin
Dec 1, 1994·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N B Javitt
Sep 14, 1993·Biochemical Pharmacology·T P Johnston, W K Palmer
May 3, 1996·Science·J L Breslow
May 1, 1997·Journal of Cardiovascular Pharmacology·T P Johnston, W K Palmer
Dec 31, 1997·Medicine and Science in Sports and Exercise·W K PalmerT P Johnston
Apr 17, 1998·Atherosclerosis·W K PalmerT P Johnston
Oct 16, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·A Tsuji
Dec 22, 1999·Journal of Cardiovascular Pharmacology·T P JohnstonW K Palmer
Mar 1, 1957·Proceedings of the Society for Experimental Biology and Medicine·S ERIKSSON
Jul 17, 1958·Acta Physiologica Scandinavica·S BERGSTROM, H DANIELSSON
Oct 13, 2006·Current Opinion in Gastroenterology·Hideyuki HyogoDavid E Cohen

❮ Previous
Next ❯

Citations

Nov 11, 2006·Pharmaceutical Research·Gilles DumortierJean Claude Chaumeil
Nov 1, 2008·The Journal of Biological Chemistry·Ahmed E EnayetAllahDavid F Grant
Mar 12, 2003·The Journal of Experimental Medicine·Orhan AktasFrauke Zipp
Jun 10, 2008·Cardiovascular Research·Leonie G Mikael, Rima Rozen
Aug 13, 2009·Journal of Atherosclerosis and Thrombosis·Hanayo TanakaKen-Ichi Hirata
Jun 5, 2014·Canadian Journal of Physiology and Pharmacology·Marwan AbdelbasetAzza M Agha
Feb 11, 2012·Canadian Journal of Physiology and Pharmacology·Tatyana A KorolenkoVassilij I Kaledin
Nov 28, 2012·Canadian Journal of Physiology and Pharmacology·Tatyana A KorolenkoAnna A Monoszon
May 25, 2004·Expert Opinion on Investigational Drugs·Paul Webb
Jul 20, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Faridah Hanim ShakirinLau Cheng Yuon
Apr 28, 2004·Trends in Endocrinology and Metabolism : TEM·John D BaxterTom S Scanlan
Feb 7, 2006·Atherosclerosis·Victoria C CoggerDavid G Le Couteur
May 13, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Joo Hyun LeeYoung-Joo Lee
Jan 29, 2016·Plastic and Reconstructive Surgery·Christopher R DavisGeoffrey C Gurtner
Sep 7, 2017·Scientific Reports·Susana Suárez-GarcíaLluís Arola
Aug 28, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nurjannatul Naim KamaruddinHabsah Mohamad

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.